Resistance Development of Cystic Fibrosis Respiratory Pathogens When Exposed to Fosfomycin and Tobramycin Alone and in Combination under Aerobic and Anaerobic Conditions

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  McCaughey, Gerard ^a   Diamond, Paul ^a   Elborn, J Stuart ^a,b   McKevitt, Matt ^c   Tunney, Michael M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; TOBRAMYCIN;

AEROBIC METABOLISM; ANAEROBIC METABOLISM; ANTIBIOTIC RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CYSTIC FIBROSIS; DRUG COMBINATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTANT; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ADULT; AEROBIOSIS; ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; CULTURE MEDIA; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOSFOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TOBRAMYCIN;

EID: 84880819676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069763     Document Type: Article

References (34)

1. French GL, (2010) The continuing crisis in antibiotic resistance. Int J Antimicrob Agents 36Suppl 3: S3-7.
2. Dodge JA, Lewis PA, Stanton M, Wilsher J, (2007) Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 29: 522-526.
3. Oliver A, (2010) Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy. International journal of medical microbiology: IJMM 300: 563-572.
4. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, et al. (2006) Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 73: 27-33.
5. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL, (2010) Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 45: 363-370.
6. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, et al. (2008) Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177: 995-1001.
7. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, et al. (2011) Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 66: 579-584.
8. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, et al. (2012) The Adult Cystic Fibrosis Airway Microbiota Is Stable over Time and Infection Type, and Highly Resilient to Antibiotic Treatment of Exacerbations. PLoS One 7: e45001.
9. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, et al. (2002) Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317-325.
10. Field TR, White A, Elborn JS, Tunney MM, (2005) Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur J Clin Microbiol Infect Dis 24: 677-687.
11. King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN, (2010) Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis 66: 181-186.
12. UK CF Trust Infection Control Working Group (2009) Antibiotic Treatment for Cystic Fibrosis.
13. McCaughey G, McKevitt M, Elborn JS, Tunney MM, (2012) Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros 11: 163-172.
14. CLSI (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Seventh Edition. CLSI document M07-A8. Pennsylvania, USA:. Clinical and Laboratory Standards Institute.
15. MacLeod DL, Barker LM, Sutherland JL, Moss SC, Gurgel JL, et al. (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64: 829-836.
16. Saiman L, (2007) Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr Respir Rev 8: 249-255.
17. Rodriguez-Rojas A, Couce A, Blazquez J, (2010) Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 54: 4948-4949.
18. Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Canton E, et al. (2006) In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 19: 252-257.
19. Thauvin C, Lemeland JF, Humbert G, Fillastre JP, (1988) Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 32: 919-921.
20. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI, (2003) Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 47: 2850-2858.
21. Ellington MJ, Livermore DM, Pitt TL, Hall LMC, Woodford N, (2006) Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 58: 848-852.
22. Nair CG, Chao C, Ryall B, Williams HD, (2013) Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa. Lett Appl Microbiol 56: 149-154.
23. Moriarty TF, McElnay JC, Elborn JS, Tunney MM, (2007) Sputum antibiotic concentrations: Implications for treatment of cystic fibrosis lung infection. Pediatric Pulmonology 42: 1008-1017.
24. Wu YL, Scott EM, Po AL, Tariq VN, (1999) Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J Antimicrob Chemother 44: 389-392.
25. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, et al. (2006) Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 58: 822-829.
26. Berlana D, Llop JM, Manresa F, Jodar R, (2011) Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Pharmacotherapy 31: 146-157.
27. Valenza G, Radike K, Schoen C, Horn S, Oesterlein A, et al. (2010) Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment. Scand J Infect Dis 42: 885-889.
28. Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, et al. (2007) Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132: 562-568.
29. Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, et al. (2012) Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection. Am J Respir Crit Care Med 185: 171-178.
30. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME, (2012) Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother 67: 255-268.
31. Olofsson SK, Cars O, (2007) Optimizing Drug Exposure to Minimize Selection of Antibiotic Resistance. Clin Infect Dis 45: S129-S136.
32. Perron GG, Kryazhimskiy S, Rice DP, Buckling A, (2012) Multidrug therapy and evolution of antibiotic resistance: when order matters. Appl Environ Microbiol 78: 6137-6142.
33. Rodriguez-Rojas A, Macia MD, Couce A, Gomez C, Castaneda-Garcia A, et al. (2010) Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One 5: e10193.
34. Macleod DL, Velayudhan J, Kenney TF, Therrien JH, Sutherland JL, et al. (2012) Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 1529-1538.